Comparison of clozapine use in Maryland and in Victoria, Australia

Psychiatric Services

Volumn 56, Issue 3, 2005, Pages 320-323

  Conley, Robert R ^a   Kelly, Deanna L ^a   Lambert, Tim J ^b   Love, Raymond C ^c  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUSTRALIA; CONTROLLED STUDY; CULTURAL FACTOR; DEMOGRAPHY; FEMALE; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD; MENTAL HEALTH; OUTPATIENT CARE; POPULATION RESEARCH; PRESCRIPTION; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; AUSTRALIA; BENZODIAZEPINES; CATCHMENT AREA (HEALTH); CLOZAPINE; CROSS-SECTIONAL STUDIES; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MARYLAND; MEDICAL RECORDS; PRESCRIPTIONS, DRUG; RISPERIDONE; SCHIZOPHRENIA;

EID: 14744303773     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.56.3.320     Document Type: Article

References (37)

1. Capuano B, Crosby IT, Lloyd EJ: Schizophrenia: genesis, receptorology, and current therapeutics. Current Medicinal Chemistry 9:521-548, 2002
2. Taleb M, Rouillon R, Petitjean F, et al: Cross-cultural study of schizophrenia. Psychopathology 29:85-94, 1996
3. Kulhara P, Chakrabarti S: Culture and schizophrenia and other psychotic disorders. Psychiatric Clinics of North America 24:449464, 2001
4. Jablensky A: Epidemiology of schizophrenia: the global burden of disease and disability. European Archives of Psychiatry and Clinical Neuroscience 250:274-285, 2000
5. Johnson DA: Observations on the dose regime of fluphenazine decanoate in maintenance therapy of schizophrenia. British Journal of Psychiatry 126:457-461, 1975
6. Kane JM: Schizophrenia. New England Journal of Medicine 334:34-41, 1996
7. Wilson WH, Ban TA, Guy W: Pharmacotherapy of chronic hospitalized schizophrenics: prescription practices. Neuropsychobiology 14:75-82, 1985
8. Paton C, Lelliott P, Harrington M, et al: Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. Journal of Psychopharmacology 17:223-229, 2003
9. Bitter I, Chou JC, Ungvari GS, et al: Prescribing for inpatients with schizophrenia: an international multi-center comparative study. Pharmacopsychiatry 36:143-149, 2003
10. Dollfus S, van Os J, Petit M: Do we need a European consensus on the use of antipsychotic medication? European Psychiatry 11:400-402, 1996
11. Lehman AF, Steinwachs DM: Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin 24:1-10, 1998
12. Mellman TA, Miller AL, Weissman EM, et al: Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms. Psychiatric Services 52:619-625, 2001
13. Marder SR: Can clinical practice guide a research agenda? Schizophrenia Bulletin 28:127-129, 2002
14. Lehman AF, Kreyenbuhl J, Buchanan RW, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin 30:193-217, 2004
15. Lehman AF, Lieberman JA, Dixon LB, et al: Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161 (suppl 2):1-56 2004
16. Miller AL, Hall CS, Buchanan RW, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry 65:500-508, 2004
17. Conley RR: Optimizing treatment with clozapine. Journal of Clinical Psychiatry 59 (suppl 3):44-48, 1998
18. Lieberman JA: Maximizing clozapine therapy: managing side effects. Journal of Clinical Psychiatry 59(suppl 3):38-43, 1998
19. Weissman EM: Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York metropolitan region. Schizophrenia Bulletin 28:31-42, 2002
20. Fayek M, Flowers C, Signorelli D, et al: Underuse of evidence-based treatments in psychiatry. Psychiatric Services 54:1453-1456, 2003
21. National Disease and Therapeutic Index Manual. International Marketing Services (IMS) Health Sept 1999
22. National Disease and Therapeutic Index Manual. International Marketing Services (IMS) Health Jan 2000
23. National Disease and Therapeutic Index Manual. International Marketing Services (IMS) Health Jan 2002
24. Wang PS, Ganz DA, Benner JS, et al: Should clozapine continue to be restricted to third-line status for schizophrenia? A decision-analytic model. Journal of Mental Health Policy and Economics 7:77-85, 2004
25. Rosenheck R, Cramer J, Allan E, et al: Cost-effectiveness of clozapine in patients with high and low levels of hospital use: Department of Veterans Affairs Cooperative Study Group on Clozapine Refractory Schizophrenia. Archives of General Psychiatry 56:565-572, 1999
26. Sernyak MJ, Rosenheck R, Desai R, et al: Impact of clozapine prescription on inpatient resource utilization. Journal of Nervous and Mental Disease 189:766-773, 2001
27. Hayhurst KP, Brown P Lewis SW: The cost-effectiveness of clozapine: a controlled, population-based mirror-image study. Journal of Psychopharmacology 16:169-175, 2002
28. Conley RR, Kelly DL, Love RC, et al: Rehospitalization risk with second-generation and depot antipsychotics. Annals of Clinical Psychiatry 15:23-31, 2003
29. Oh PI, Iskedjian M, Addis A, et al: Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Canadian Journal of Clinical Pharmacology 8:199-206, 2001
30. Copolov DL, Bell WR, Benson WJ, et al: Clozapine treatment in Australia: a review of haematological monitoring. Medical Journal of Australia 168:495-497, 1998
31. Clozaril Patient Monitoring System. Available at www.mhri.edu.au/cpms
32. Drew LR, Griffiths KM, Hodgson DM: A five year follow-up study of the use of clozapine in community practice. Australia and New Zealand Journal of Psychiatry 36:780-786, 2002
33. Fleischhacker WW, Hummer M, Kurz M, et al: Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. Journal of Clinical Psychiatry 55(suppl B):78-81, 1994
34. Angermeyer MC, Kuhn L, Goldstein JM: Gender and the course of schizophrenia: differences in treated outcomes. Schizophrenia Bulletin 16:293-307, 1990
35. Goldner EM, Bilsker D: Evidence-based psychiatry. Canadian Journal of Psychiatry 40:97-101, 1995
36. Cooper B: Evidence-based mental health policy: a critical appraisal. British Journal of Psychiatry 183:105-113, 2003
37. Hickie IB, Scott EM, Davenport TA: Enhancing the evidence base for clinical psychiatry: are practice surveys a useful tool? Medical Journal of Australia 171:315-318, 1999